RCT on inactivated whole-virion SARS-CoV-2 vaccine (Corona | UPDATES IN MEDICINE
RCT on inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac)
Nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group and 32 cases were reported in the placebo group 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4–92·1; p<0·0001).
● Interpretation - CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile.
